21 million euros
Leuven – TiGenix, a Belgian biomedical company focused on innovative local treatments for damaged and osteoarthritic joints has gone public at Euronext. The company raised a40 million through the sale of 8 million shares at a5 in an IPO and private placement. The price was in the company’s proposed range of a4.20 to a5.50. ING and Piper Jaffray are joint bookrunners and joint lead managers. Petercam was co-lead manager. TiGenix’s ChondroCelect has completed a phase III trial to treat cartilage defects.